Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
Authors
Keywords
-
Journal
BONE MARROW TRANSPLANTATION
Volume 50, Issue 8, Pages 1024-1029
Publisher
Springer Nature
Online
2015-04-21
DOI
10.1038/bmt.2015.83
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myélome
- (2014) Murielle Roussel et al. JOURNAL OF CLINICAL ONCOLOGY
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data
- (2014) Antonio Palumbo et al. LANCET ONCOLOGY
- Autologous Transplantation and Maintenance Therapy in Multiple Myeloma
- (2014) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation
- (2014) Guillemette Fouquet et al. Journal of Cancer
- Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial
- (2013) U.-H. Mellqvist et al. BLOOD
- A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial
- (2013) A. K. Stewart et al. BLOOD
- Bortezomib-containing induction regimens in transplant-eligible myeloma patients
- (2013) Ajay K. Nooka et al. CANCER
- Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment
- (2013) G. J. Morgan et al. CLINICAL CANCER RESEARCH
- Importance of Achieving Stringent Complete Response After Autologous Stem-Cell Transplantation in Multiple Myeloma
- (2013) Prashant Kapoor et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study
- (2013) Andy C. Rawstron et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal Residual Disease in Multiple Myeloma
- (2013) Nikhil C. Munshi et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials
- (2013) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma
- (2013) X Leleu et al. LEUKEMIA
- VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT
- (2013) E Terpos et al. LEUKEMIA
- Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma
- (2012) Angelo Maiolino et al. AMERICAN JOURNAL OF HEMATOLOGY
- Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study
- (2012) L. Rosinol et al. BLOOD
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma
- (2012) M. Cavo et al. BLOOD
- Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial
- (2012) Pieter Sonneveld et al. JOURNAL OF CLINICAL ONCOLOGY
- Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis
- (2012) Yuki Kagoya et al. LEUKEMIA RESEARCH
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis
- (2011) G. J. Morgan et al. BLOOD
- Can multiple myeloma become a curable disease?
- (2011) J. F. San-Miguel et al. HAEMATOLOGICA
- Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
- (2011) G. J. Morgan et al. HAEMATOLOGICA
- Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
- (2011) Philippe Moreau et al. LANCET ONCOLOGY
- Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial
- (2010) Jean-Luc Harousseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Reiterative Survival Analyses of Total Therapy 2 for Multiple Myeloma Elucidate Follow-Up Time Dependency of Prognostic Variables and Treatment Arms
- (2010) Bart Barlogie et al. JOURNAL OF CLINICAL ONCOLOGY
- Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
- (2010) Marco Ladetto et al. JOURNAL OF CLINICAL ONCOLOGY
- Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study
- (2010) Michele Cavo et al. LANCET
- The role of complete response in multiple myeloma
- (2009) J.-L. Harousseau et al. BLOOD
- A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma
- (2009) H. M. Lokhorst et al. BLOOD
- The Importance of Complete Response in Outcomes in Myeloma
- (2009) Ajay Nooka et al. CANCER JOURNAL
- Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities
- (2008) B. Barlogie et al. BLOOD
- Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
- (2008) B. Paiva et al. BLOOD
- Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma
- (2008) Bart Barlogie et al. CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now